Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea

  • Moon, Byung Suk (Department of Pediatrics, Eulji University Hospital, Eulji University College of Medicine) ;
  • Choi, Jun Seok (Department of Pediatrics, Eulji University Hospital, Eulji University College of Medicine) ;
  • You, Chur Woo (Department of Pediatrics, Eulji University Hospital, Eulji University College of Medicine)
  • Received : 2012.09.13
  • Accepted : 2012.10.25
  • Published : 2013.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study was to investigate prophylactic treatment effects in Korean patients with severe hemophilia A. Methods: A prospective study of 32 severe hemophilia A patients was conducted with the approval of the Institutional Review Board at the Eulji University Hospital. Two patients received primary prophylaxis; whereas, the other 30 patients were divided into 2 groups-secondary prophylaxis (n=15) and on-demand (n=15)-on the basis of their consent for secondary prophylaxis. A 20-25 IU/kg dose of factor VIII concentrate was administered to the primary and secondary prophylaxis group patients every 3 days for 1 year. The prophylactic effect was evaluated by observing changes in the Pettersson scores, annual number of total and joint bleeds, and factor VIII consumption for 1 year. Results: No moderate or severe bleeding was observed, and the Pettersson scores remained unchanged during the prophylaxis period in the patients who received primary prophylactic treatment. After the treatment was changed from on-demand to secondary prophylaxis, the annual number of total and joint bleeds in the secondary prophylaxis group decreased by $64.4%{\pm}13.0%$ and $70.0%{\pm}15.2%$, respectively. The average increase in Pettersson scores within 1 year was $0.5{\pm}0.8$ and $1.3{\pm}1.1$ in the secondary prophylaxis and on-demand groups, respectively. Prophylactic effects were also observed in patients >17 years who had nearly the same initial Pettersson scores. Conclusion: Intermediate-dose prophylactic treatment may delay hemarthropathy progression and prevent its occurrence in Korean severe hemophilia A patients.

Keywords

References

  1. Arnold WD, Hilgartner MW. Hemophilic arthropathy: current concepts of pathogenesis and management. J Bone Joint Surg Am 1977;59:287-305. https://doi.org/10.2106/00004623-197759030-00001
  2. Rodriguez-Merchan EC. The destructive capabilities of the synovium in the haemophilic joint. Haemophilia 1998;4:506-10. https://doi.org/10.1046/j.1365-2516.1998.440506.x
  3. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-9. https://doi.org/10.1111/j.1365-2796.1994.tb00815.x
  4. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32. https://doi.org/10.1111/j.1365-2796.1992.tb00546.x
  5. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients: a long-term follow-up. J Intern Med 1997;241:395-400. https://doi.org/10.1046/j.1365-2796.1997.130135000.x
  6. van den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001;112:561-5. https://doi.org/10.1046/j.1365-2141.2001.02580.x
  7. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44. https://doi.org/10.1056/NEJMoa067659
  8. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965:Suppl 77:3-132.
  9. Ingram GI. The history of haemophilia. J Clin Pathol 1976;29:469-79. https://doi.org/10.1136/jcp.29.6.469
  10. Medical and Scientific Advisory Council. MASAC Recommendations concerning prophylaxis in children with severe hemophilia [MASAC document #193]. New York: National Hemophilia Foundation Medical Bulletin, 1994.
  11. Fischer K, Astermark J, van der Bom JG, Ljung R, Berntorp E, Grobbee DE, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002;8:753-60. https://doi.org/10.1046/j.1365-2516.2002.00694.x
  12. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001;7:99-102. https://doi.org/10.1046/j.1365-2516.2001.00471.x
  13. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980;(149):153-9.
  14. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005;11:438-43. https://doi.org/10.1111/j.1365-2516.2005.01124.x
  15. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, de Kleijn P, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002;99:2337-41. https://doi.org/10.1182/blood.V99.7.2337
  16. van den Berg HM, De Groot PH, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 2007;5 Suppl 1:151-6. https://doi.org/10.1111/j.1538-7836.2007.02503.x
  17. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998;4:413-7. https://doi.org/10.1046/j.1365-2516.1998.440413.x
  18. Blanchette VS, Babyn P, Chan A, Card R, Demers C, Gill K, et al. Long term (10 year) results from the Canadian hemophilia primary prophylaxis study [abstract]. J Thromb Haemost 2009;7 Suppl 2:54-5.
  19. Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999;5:378-85. https://doi.org/10.1046/j.1365-2516.1999.00347.x
  20. Fischer K, van Hout BA, van der Bom JG, Grobbee DE, van den Berg HM. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol 2002;43:528-32. https://doi.org/10.1258/rsmacta.43.5.528
  21. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85:560.
  22. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005;11:326-34. https://doi.org/10.1111/j.1365-2516.2005.01107.x
  23. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year followup of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004;10:689-97. https://doi.org/10.1111/j.1365-2516.2004.01036.x
  24. Collins PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, Fritsch S, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009;7:413-20. https://doi.org/10.1111/j.1538-7836.2008.03270.x
  25. Blanchette VS, Shapiro AD, Liesner RJ, Hernandez Navarro F, Warrier I, Schroth PC, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008;6:1319-26. https://doi.org/10.1111/j.1538-7836.2008.03032.x
  26. Carlsson M, Berntorp E, Bjorkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997;3:96-101. https://doi.org/10.1046/j.1365-2516.1997.00091.x
  27. Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003;9 Suppl 1:101-8. https://doi.org/10.1046/j.1365-2516.9.s1.4.x
  28. Collins P, Fischer K, Blanchette VS, Bjorkman S, Oh M, Schroth P, et al. Effect of normal variation in factor VIII pharmacokinetics on prophylactic dosing requirements in severe classical hemophilia. Blood 2008;112:1222.
  29. Berntorp E, Bjorkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003;9:353-9. https://doi.org/10.1046/j.1365-2516.2003.00762.x
  30. Fischer K, Bom JG, Mauser-Bunschoten EP, Roosendaal G, Berg HM. Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia 2005;11:43-8. https://doi.org/10.1111/j.1365-2516.2005.01065.x
  31. Schimpf K, Fischer B, Rothmann P. Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study. Scand J Haematol Suppl 1977;30:79-80.

Cited by

  1. Modified Primary Prophylaxis in Previously Untreated Patients With Severe Hemophilia A in Iran vol.40, pp.3, 2013, https://doi.org/10.1097/mph.0000000000001082
  2. Principles of haemophilia care: The Asia‐Pacific perspective vol.24, pp.3, 2018, https://doi.org/10.1111/hae.13425